Abstract: The present specification provides a compound represented by Chemical Formula 1, a colorant composition, a resin composition, a photosensitive material, a color filter and a display device comprising the same.
Type:
Grant
Filed:
February 26, 2020
Date of Patent:
February 1, 2022
Assignee:
LG CHEM, LTD.
Inventors:
Jongho Park, Dami Lee, Seung Jin Yang, Jihye Jung
Abstract: The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.
Type:
Grant
Filed:
November 6, 2015
Date of Patent:
February 1, 2022
Assignee:
Dana-Farber Cancer Institute, Inc.
Inventors:
James E. Bradner, Jun Qi, Kwok-kin Wong
Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
Type:
Grant
Filed:
June 9, 2020
Date of Patent:
January 18, 2022
Assignee:
Sunshine Lake Pharma Co., Ltd.
Inventors:
Yingjun Zhang, Qingyun Ren, Changhua Tang, Xiaohong Lin, Junjun Yin, Kai Yi
Abstract: Plakortinic acids A (2) and B (3), two polyketide endoperoxides having an unprecedented bicyclo[4.2.0]octene unit, were isolated as minor constituents from the sponge-sponge symbiotic association Plakortis halichondrioides-Xestospongia deweerdtae from Puerto Rico, along with the known epiplakinic acid F (1). The molecular structures of 2 and 3 were determined mainly on the basis of NMR spectroscopy. Due to the structural similarities, 2 and 3 are thought to be biosynthetically related to 1. Biological screening for cytotoxic activity against two human tumor cell lines revealed that these novel metabolites are very active at low to sub-micro molar concentration.
Type:
Grant
Filed:
June 6, 2017
Date of Patent:
December 14, 2021
Assignee:
University of Puerto Rico
Inventors:
Abimael D. Rodriguez Pierluissi, Carlos Jimenez Romero
Abstract: The disclosure provides compounds of formula (I): said compounds being inhibitors of Kv3 channels and of use in the prophylaxis or treatment of related disorders.
Type:
Grant
Filed:
August 4, 2020
Date of Patent:
December 14, 2021
Assignee:
AUTIFONY THERAPEUTICS LIMITED
Inventors:
Giuseppe Alvaro, Paolo Dambruoso, Simona Tommasi, Anne Decor, Charles Large, Agostino Marasco
Abstract: Quinoline compounds are disclosed that have a formula represented by the following: and wherein Cy, R1, R4a, R4b, and n are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diabetes complications, inflammation, and neurodegeneration, obesity, cancer, ischemia/reperfusion injury, cardiovascular disease and other diseases related to RAGE activity.
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
December 7, 2021
Inventors:
Ann Marie Schmidt, Ravichandran Ramasamy, Alexander Shekhtman, Vivek Rai, Michaele B. Manigrasso
Abstract: The present invention relates to opiate derived compositions and their antagonists useful in therapeutic areas associated with opioid receptor modulation. A 3-hexadienoate modification of the opioids is formulated to improve opiates' engagement of the opioid receptors when given orally. A 3-hexadienoate modification of Nalbuphine or a pharmaceutically acceptable salt of thereof to improve quality of pain management when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation. A 3-hexadienoate modification of the opioids antagonists is formulated to improve inhibition of the opioid receptors when given orally. A 3-hexadienoate modification of Naloxone or a pharmaceutically acceptable salt of thereof to improve quality of Sobering when given intravenously, intranasally, transdermally, sublingually, rectally, topically, intramuscularly, subcutaneously or via inhalation.
Type:
Grant
Filed:
August 14, 2019
Date of Patent:
November 30, 2021
Assignee:
Kappa-Pharma LLC
Inventors:
Georgiy Nikonov, Levon Isakulyan, Michael Voronkov
Abstract: The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.
Type:
Grant
Filed:
December 1, 2017
Date of Patent:
November 30, 2021
Assignee:
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
Abstract: Disclosed herein are methods and processes of preparing niraparib and pharmaceutically acceptable salts thereof, and intermediates and their salts useful for the synthesis of niraparib.
Type:
Grant
Filed:
April 24, 2018
Date of Patent:
November 2, 2021
Assignee:
Tesaro, Inc.
Inventors:
Alistair Stewart, Anthony Joseph Toto, Frank Xing Chen, George Wu
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
Type:
Grant
Filed:
July 22, 2020
Date of Patent:
November 2, 2021
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Gregory L. Adams, Jason M. Cox, John S. Debenham, Scott Edmondson, Eric J. Gilbert, Yan Guo, Yu Jiang, Hubert Josien, Hyunjin M. Kim, Ping Lan, Shouwu Miao, Christopher W. Plummer, Murali Rajagopalan, Unmesh Shah, Zhongxiang Sun, Quang T. Truong, Feroze Ujjainwalla, Francisco Velazquez, Srikanth Venkatraman, Takao Suzuki, Nengxue Wang
Abstract: The present invention is directed to cyclopropylamine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).
Type:
Grant
Filed:
March 6, 2020
Date of Patent:
October 19, 2021
Assignee:
XWPHARMA LTD.
Inventors:
Jia-Ning Xiang, Xuesong Xu, Yi Feng, Xianbo Liu, Wai-Si Eng
Abstract: The disclosure provides a process of making the compound of Formula I, and pharmaceutically acceptable salts thereof: and the process of making the intermediate of Formula III: wherein PG is as defined as set forth in the specification.
Type:
Grant
Filed:
December 22, 2017
Date of Patent:
September 21, 2021
Assignee:
Minoryx Therapeutics S.L.
Inventors:
Ana Maria GarcĂa Collazo, Wolter Ten Hoeve, Johannes Nicolaas Koek, Johannes B. M. Rewinkel, Sander De Wilde
Abstract: A process for producing crystals of a compound represented by the following formula (I): by crystallizing the compound from an aqueous solution containing the compound and an inorganic salt, such as sodium chloride. Such crystals can be subjected to lyophilization to provide a lyophilized composition having a desirable storage stability.
Abstract: The present invention is related to an improved process for the preparation of Pomalidomide with higher yields and high purity. Particularly the present invention relates to form A preparation of Pomalidomide and its purification. wherein the present process doesn't involve use of dioxane solvent and avoids higher temperatures.
Type:
Grant
Filed:
August 22, 2016
Date of Patent:
September 7, 2021
Assignee:
Natco Pharma Limited
Inventors:
Durga Prasad Konakanchi, Buchappa Gongalla, Dharmendher Ragidi, Uma Naresh Babu Kotra, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
August 31, 2021
Assignee:
Array BioPharma Inc.
Inventors:
Ronald Jay Hinklin, Shelley Allen, Patrick Barbour, Adam Cook, Joshua Dahlke, John Gaudino, Ellen Laird, Oren T. McNulty, Qian Zhao
Abstract: The present disclosure provides a compound of Formula (I) or pharmaceutically acceptable salt, stereoisomers thereof, a pharmaceutical composition comprising the compound, and a method to treat or prevent neurodegenerative diseases using the compound.
Type:
Grant
Filed:
February 21, 2020
Date of Patent:
August 24, 2021
Assignee:
1ST Biotherapeutics, Inc.
Inventors:
Jinhwa Lee, Suyeon Jo, Keonseung Lim, A Yeong Park, Jae Eun Kim, Misoon Kim, Seung Mook Lim
Abstract: This disclosure relates to lipid disulfide prodrugs and in particular to lipid disulfide phosphodiester nucleosides and derivatives thereof, pharmaceutical compositions, and uses related thereto. According to one embodiment of the disclosure there is provided a compound of Formula I, or pharmaceutically acceptable salts or derivatives thereof, wherein substituents are disclosed herein.
Abstract: This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
Type:
Grant
Filed:
January 22, 2020
Date of Patent:
August 10, 2021
Assignee:
Centrexion Therapeutics Corporation
Inventors:
Doris Riether, Florian Paul Christian Binder, Henri Doods, Stephan Georg Mueller, Janet Rachel Nicholson, Achim Sauer